Rockefeller Capital Management
CTXR icon

Rockefeller Capital Management’s Citius Pharmaceuticals CTXR Stock Holding History

Rockefeller Capital Management’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2
Closed – – 2386
2022
Q4 		$0 Hold
2
– – ﹤0.01% 3900
2022
Q3 		$0 Hold
2
– – ﹤0.01% 3959
2022
Q2 		$0 Buy
+2
New +$55 ﹤0.01% 4145

Other funds holding CTXR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Rockefeller Capital Management's CTXR Position: Q1 2023 in Review

Rockefeller Capital Management sold out of Citius Pharmaceuticals (CTXR) in Q1 2023, closing a stake of 2 shares.

Rockefeller Capital Management first reported a position in CTXR in Q2 2022 and held it in 3 quarters. The position peaked at $0 in Q4 2022. 55 funds tracked by Wall St. Rank hold CTXR as of Q1 2023.

  • Rockefeller Capital Management reported no remaining Citius Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Rockefeller Capital Management sold 2 Citius Pharmaceuticals shares in Q1 2023.
  • Rockefeller Capital Management first reported a position in Citius Pharmaceuticals in Q2 2022 and held it in 3 quarters.
  • Rockefeller Capital Management's Citius Pharmaceuticals position peaked at $0 in Q4 2022.
  • 55 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q1 2023.

Based on Rockefeller Capital Management's 13F filing for Q1 2023, filed 16 May 2023.